Experimental antibody takes aim at tough lymphoma

NCT ID NCT02520791

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting a protein on immune cells to potentially slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MEDI-570 (an antibody that targets a protein on immune cells to help fight cancer)

What this could lead to

If successful, this could point toward a new treatment option for certain hard-to-treat T-cell lymphomas.

What could go wrong

This is a very early phase 1 trial with only 21 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioimmunoblastic T-cell lymphoma follicular lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides peripheral T-cell lymphoma, not otherwise specified primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma primary cutaneous peripheral T-cell lymphoma not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE RECURRENT GRADE 1 FOLLICULAR LYMPHOMA RECURRENT GRADE 2 FOLLICULAR LYMPHOMA RECURRENT GRADE 3A FOLLICULAR LYMPHOMA RECURRENT MATURE T- CELL AND NK-CELL NON-HODGKIN LYMPHOMA RECURRENT MYCOSIS FUNGOIDES RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA REFRACTORY FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA STAGE IB MYCOSIS FUNGOIDES AJCC V7 STAGE II MYCOSIS FUNGOIDES AJCC V7 STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE III MYCOSIS FUNGOIDES AJCC V7 STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE IV MYCOSIS FUNGOIDES AJCC V7

Contacts and locations

Show contact details

Locations

BCCA-Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467, United States
Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461, United States
Montefiore Medical Center-Weiler Hospital

The Bronx, New York, 10461, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Yale University

New Haven, Connecticut, 06520, United States